PAVmed Inc.

PAVmed Inc.

PAVmed Inc. is a publicly traded medical device company headquartered in the United States, focused on the development and commercialization of innovative healthcare technologies. The firm operates through a portfolio model, advancing multiple product candidates across subsidiaries including Lucid Diagnostics (esophageal cancer detection), Veris Health (digital health), and PAVmed's own pipeline of minimally invasive devices. PAVmed's strategy centers on addressing unmet clinical needs in areas such as cancer diagnostics, interventional pain management, and vascular access. The company's portfolio includes the EsoGuard esophageal DNA test, the EsoCheck cell collection device, and the PortIO implantable intraosseous vascular access system. Geographic focus is primarily the US market, with clinical and regulatory activities targeting FDA clearance and commercial partnerships. As a publicly traded entity (Nasdaq: PAVM), PAVmed's scale is measured by market capitalization rather than AUM. The firm employs a lean team structure, with key leadership including CEO Dennis McGrath and Executive Chairman Lishan Aklog, a cardiothoracic surgeon and former medical device executive. The company has raised capital through public offerings and grants, with no disclosed asset management or family office operations. Recent operational events include the FDA clearance of the EsoCheck device in 2022 and ongoing clinical trials for EsoGuard. PAVmed's structural differentiator is its subsidiary-driven model: rather than licensing its technologies to larger partners, the firm spin-out separate public or private entities (Lucid Diagnostics, Veris Health) to develop and commercialize specific products independently. This structure allows PAVmed to retain upside across multiple verticals while distributing risk and enabling targeted capital raises for each subsidiary.